Pharmacological properties of total flavonoids in Scutellaria baicalensis for the treatment of cardiovascular diseases

This publication has 92 references indexed in Scilit:

• Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)—possible therapeutic perspectives
  Journal of the American Society of Hypertension, 2011
• A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats
  European Journal of Pharmacology, 2011
• Baicalin increases VEGF expression and angiogenesis by activating the ERR /PGC-1 pathway
  Cardiovascular Research, 2010
• Scutellarin promotes in vitro angiogenesis in human umbilical vein endothelial cells
  Biochemical and Biophysical Research Communications, 2010
• The anti‐inflammatory effect of baicalin on hypoxia/reoxygenation and TNF‐α induced injury in cultural rat cardiomyocytes
  Phytotherapy Research, 2009
• Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction
  Toxicology, 2009
• Baicalein Reduces Inflammatory Process in a Rodent Model of Diabetic Retinopathy
  Investigative Ophthalmology & Visual Science, 2009
• Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2
  Life Sciences, 2008
• Wogonin Inhibits IL-6-Induced Angiogenesis via Down-Regulation of VEGF and VEGFR-1, not VEGFR-2
  Planta Medica, 2006
• Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats
  Journal of Pharmacy and Pharmacology, 2003